Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression

Launched by CENTER FOR EYE RESEARCH AUSTRALIA · Feb 1, 2021

Keywords

ClinConnect Summary

The clinical trial titled "Project AMD" is focused on understanding age-related macular degeneration (AMD), a condition that leads to vision loss, affecting many people worldwide, including nearly two million Australians. This study aims to learn more about what causes AMD, how it differs in severity among individuals, and how it progresses over time. Researchers will gather information through non-invasive eye imaging, biological samples, and feedback from participants about their experiences. By doing this, they hope to identify factors that influence the progression of the disease.

To participate in this study, you must be at least 18 years old and have either AMD or normal age-related changes in your eyes. Unfortunately, if you have other eye conditions or health issues that could affect the study, you may not be eligible. Participants will undergo various assessments but can expect a supportive environment throughout the process. This trial is currently recruiting participants of all genders, and your involvement could help improve our understanding of AMD for future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years of age or older; and
• • 2. either AMD (defined as having at least a medium druse \>63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants
• Exclusion Criteria:
• • 1. ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or
• • 2. any participant with any mental or physical impairment that prevents them from signing an informed consent form or participating in this study.